circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis
The Journal of Gene Medicine · 2023
DOI: 10.1002/jgm.3478 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2023. Verfasst von Shu Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs, RNA, Circular. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Non‐small‐cell lung cancer (NSCLC) is a common cancer. Chemotherapeutic drug resistance limits the therapeutic effect of NSCLC and leads to a poor prognosis. As a result, new specific targets may be better identified by studying the mechanism of drug resistance to cisplatin in NSCLC.
Methods
In the present study, we performed a quantitative real‐time polymerase chain reaction and western blotting to detect mRNA and protein levels. The proliferation of cells was analyzed by a Cell Counting Kit‐8 and colony formation assays. Cell invasion was measured via the Transwell assay. A scratch assay was performed to measure cell migration in cisplatin (DDP)‐resistant NSCLC cells. Apoptosis of cells was examined using flow cytometry.
Results
We found that circANKRD28 was notably decreased in NSCLC. The results showed that circANKRD28 expression was not affected, and its half‐life was more than 12 h. Functional experiments revealed that circANKRD28 overexpression inhibited DDP resistance in NSCLC cells in vitro. Mechanistic findings demonstrated that circANKRD28 regulated tumor cell progression and DDP sensitivity through the miR‐221‐3p/SOCS3 axis.
Conclusions
The present study revealed the regulatory effects and molecular mechanism of circANKRD28 on the development and cisplatin resistance in NSCLC, which may provide experimental basis and theoretical support to identify new targets for therapy of DDP resistance in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
ORCID-Profile: Haicheng Tang
Zitieren
APA
Song, S., Shi, Y., Zeng, D., Xu, J., Yang, Y., Guo, W., Zheng, Y., & Tang, H. (2023). circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3478
Vancouver
Song S, Shi Y, Zeng D, Xu J, Yang Y, Guo W, et al. circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis. The Journal of Gene Medicine. 2023. doi:10.1002/jgm.3478
BibTeX
@article{Song2023,
author = {Song, Shu and Shi, Yuhan and Zeng, Dong and Xu, Jingjing and Yang, Yuexiang and Guo, Wenjuan and Zheng, Ye and Tang, Haicheng},
title = {circANKRD28 inhibits cisplatin resistance in non‐small‐cell lung cancer through the miR‐221‐3p/SOCS3 axis},
journal = {The Journal of Gene Medicine},
year = {2023},
doi = {10.1002/jgm.3478}
}
EUVIMED